Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - MARCH 2013

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Asenapine - Sublingual Tablets
Bevacizumab
Bupropion - Sustained Release Tablets
Bupropion -Tablets
Carbamazepine - Extended Release Tablets
Carbamazepine - Tablets
Carbamazepine- Chewable Tablets
Carbamazepine- Oral Suspension
Cetuximab
Clozapine - Oral Tablets
Degarelix - for Injection
Dronedarone - Tablets
Galsulfase
Infliximab
Losartan
Meropenem - for Injection
Metoprolol - 50mg/100mg Tablets
Metoprolol - 5mg/5ml Injection
Naproxen - Delayed-Release Tablets
Naproxen - Tablets
Naproxen - Tablets
Norfloxacin - Tablets
Pramipexole - Extended Release Tablets
Pramipexole - Tablets
Propafenone - Tablets
Silver Sulfadiazine - Cream
Sirolimus - Oral Suspension and Tablets
Solifenacin - Tablets
Sucralfate - Suspension
Sucralfate -Tablets
Ticagrelor -Tablets
Triptorelin Pamoate for Injectable Suspension
Ziprasidone - Capsules and Oral Suspension
Ziprasidone - Injection

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Get Health and Wellness Secrets from Our Engaging eBooks
Stay Connected
Available on the Android Market Available on the App Store